Influence of supplemented coated-cysteamine on morphology, apoptosis and oxidative stress status of gastrointestinal tract

Hongnan Liu 1,2,3*, Miaomiao Bai 1,4†, Bie Tan 1, Kang Xu 1,2, Rong Yu 2, Ruilin Huang 1,2 and Yulong Yin 1,2,4*

Abstract

Background: Cysteamine was coated to cover its odor and maintain the stability. However, coated cysteamine (CC) has not been clearly evaluated for its effects on the gastrointestinal mucosa status. We hypothesize that the appropriate CC supplementation in diet impacts the stomach and intestinal mucosa variously through regulating the morphology, apoptosis, and oxidative stress status in model of pigs.

Results: The results showed that villus height increased (P < 0.05), and crypt depth decreased (P < 0.05) in the ileum when pigs were fed the diet with low cysteamine (LCS) compared with the control diet. The ileal lesion score in the LCS group was significantly (P < 0.01) lower than that in the control group, while the gastric lesion score in the CC group was significantly (P < 0.01) higher compared with that of the control group. It also showed that the activities of total superoxide dismutase (T-SOD) and diamine oxidase (DAO) were upregulated (P < 0.05) in the LCS group. In addition, Bax and caspase 3 immunoreactivity increased (P < 0.01), and Bcl-2 immunoreactivity decreased (P < 0.01) in the gastric mucosa of pigs fed the diet with high cysteamine (HCS). The Bax and caspase 3 immunoreactivity decreased (P < 0.01), and Bcl-2 immunoreactivity increased (P < 0.01) in ileum mucosa of pigs fed the HCS diet.

Conclusions: Although moderate dietary coated cysteamine showed positive effects on GI mucosal morphology, apoptosis, and oxidative stress status, the excess coated cysteamine may cause apoptosis leading to GI damage in pigs.

Keywords: Cysteamine, Coating technology, Gastrointestinal tract, Pigs

Background

Cysteamine is used in oral therapy to treat cystinosis, which is an autosomal recessive lysosomal storage disease caused by mutations in the CTNS, which is the gene encoding the protein cystinosin in human [1]. Being dehydrated from cysteine, cysteamine is the simplest stable aminothiol. It is used as the hydrochloride salt, because it is readily oxidized to the disulfides in the presence of air. Cysteamine also improves growth of children with cystinosis [2, 3]. As a feed additive, it shows stable improvement in protein digestion and meat colour in finishing pigs [4–6]. It decreases protein breakdown, regulates hormone secretion, and reduces back fat.

Oral formulations of cysteamine may cause adverse effects, including the reduction of motor activity and generalized haemorrhage in the gastrointestinal tract and kidneys. An oral dose of 660 mg kg$^{-1}$ cysteamine bitartrate was fatal to rats. We found a low dose of dietary inclusion of cysteamine (at 30 mg kg$^{-1}$) improved growth performance and carcass quality [4]. However, the stomach fluid pH value was decreased to 2.8 (at 50 mg kg$^{-1}$) from 3.8 without cysteamine supplement. Oral cysteamine results in increasing gastrin and gastric acid production in laboratory animals [7–9]. Children with cystinosis and oral cysteamine administration were found to have a three-fold increase in gastric acid production and a 50% rise in serum gastrin levels above baseline [10, 11]. Thus, gastrointestinal (GI) symptoms are common in the animal receiving long term oral cysteamine. On this account, cysteamine is used to induce intestinal ulceration in an

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
animal model. In addition to mucosal injury, a high dose (>300 mg/kg) in a single subcutaneous injection may induce hypotension and neurological symptoms [12].

An enteric coating is a useful strategy for the oral medication or feed additive that prevents its dissolution or disintegration in the acidic environment of the stomach [13]. Ten years ago, the enteric coated cysteamine was firstly reported to reduce daily administration for patients with cystinosis [14]. However, the effect of enteric coated cysteamine on the gastrointestinal mucosa and the optimum additive range has not been systematically evaluated. Therefore, the current study aims to quantify the adverse effects of dietary CC on morphology, apoptosis, and oxidative stress status of the gastrointestinal tract in the animal model of young pigs. The results of this study may further elucidate the role of the gut on the systemic bioavailability of dietary coated cysteamine in young pigs.

**Results**

**Mucosal MDA, T-SOD, T-AOC and DAO activity**

The LCS diet elevated the activity of ileum mucosal T-SOD compared to that of the control group ($P < 0.05$) (Fig. 1b). No significant difference was found in T-SOD activity between the HCS and control group. The activity of ileum mucosal DAO was also increased in the LCS group, but not that of HCS ($P < 0.05$), in comparison with that of the control group (Fig. 1d). However, dietary coated cysteamine showed no effects on mucosal T-AOC and MDA concentrations among the groups.

**GI morphology and lesions**

GI morphology in ileal was determined to evaluate the effects caused by dietary cysteamine (Table 1). Supplementation of low coated cysteamine increased ileal villus height and reduced the crypt depth ($P < 0.05$). Dietary high coated cysteamine also reduced the ileal crypt ($P < 0.05$). Villus height: crypt (V/C) ratio was increased by LCS diet compared to that of the control diet ($P < 0.05$).

To explore the effects of coated cysteamine on pigs’ intestinal membrane barrier, we observed intestine pathologic sections and determined the intestinal mucous damage score (Table 1). The HCS group had a higher ileal lesion score compared to the control group ($P < 0.05$), whereas LCS had lower one ($P < 0.05$). In the stomach, the lesion score was increased in the HCS group ($P < 0.05$). No histological damage was found in the GI tissue of the control pigs (Fig. 2). Cell counting on the intestine pathologic section showed no effects on the amounts of intraepithelial lymphocytes, mucosal mast cells, and peyer patches induced by dietary coated cysteamine. The number of submucosal mast cells was significantly increased by the HCS diet ($P < 0.05$).

![Fig. 1](image-url) Ileum mucosal MDA (a), T-SOD (b), T-AOC (c) and DAO (d) activity. CON = pigs in the negative control group were fed a basal diet; LCS and HCS = pigs in coated cysteamine group were fed a basal diet supplemented with 35 and 280 mg/kg of cysteamine. * presents significant changes compared with CON group. Values are mean ± SEM, $n = 8$. 

Liu et al. BMC Veterinary Research (2019) 15:328
Apoptotic marker expression by ileum compartment

Apoptotic marker expression in the ileal tissue showed that bax immunoreactivity in the ileum basilar villus was reduced in the LCS group and increased in the HCS group compared to that of the control group (P < 0.05, Table 2). Caspase 3 immunoreactivity was increased (P < 0.05), and bcl-2 immunoreactivity was decreased (P < 0.05) in both the apical and basilar villus of pigs fed the HCS diet, whereas, the LCS diet reduced Caspase 3 immunoreactivity and elevated the bcl-2 immunoreactivity (P < 0.05). Immunohistochemical (IHC) staining to identify cells expressing anti-apoptotic bcl-2, pro-apoptotic caspase 3, and bax proteins in the gastric and ileum mucosa showed similar trends (Figs. 3 and 4).

Mucosal protein, DNA and RNA contents in ileal mucosa

In comparison with the control group, dietary supplementation of coated cysteamine had no effects on DNA
concentrations, or the RNA/DNA or protein/DNA ratios in the ileum (Table 3).

**Discussion**

Cysteamine is formed by the decarboxylation of cysteine and the component of Coenzyme A. It is endogenously synthesized, metabolized and excreted rapidly by the animal organism [15]. Its use was approved as a dietary supplement by the FDA in 2004. In animal husbandry, cysteamine is used as a feed additive in recent years. EMEA (The European Agency for the Evaluation of Medicinal Products) summarized the oral LD<sub>50</sub> value of cysteamine hydrochloride in mice is 625 mg/kg ~ 1352 mg/kg [16]. In vivo, it is quickly absorbed from the intestinal tract, and metabolized to cystamine, cysteine, glutathione and taurine. The reactivity of the compound is due to the SH and the NH2 group in the molecule. Because of its ability to produce somatostatin in the rat stomach,

### Table 2 Apoptotic marker expression by intestinal compartment

| Marker, by group | ileum apical villus | ileum basilar villus |
|------------------|---------------------|---------------------|
| **Bax**          |                     |                     |
| CON              | 11,349 ± 897<sup>a,b</sup> | 2276 ± 211<sup>a</sup> |
| LCS              | 8603 ± 727<sup>a</sup> | 1522 ± 157<sup>b</sup> |
| HCS              | 14,982 ± 1029<sup>b</sup> | 4372 ± 348<sup>b</sup> |
| **Bcl-2**        |                     |                     |
| CON              | 8539 ± 1042<sup>a</sup> | 2520 ± 253<sup>a</sup> |
| LCS              | 11,653 ± 1532<sup>a</sup> | 4035 ± 525<sup>b</sup> |
| HCS              | 5186 ± 707<sup>b</sup> | 1243 ± 142<sup>c</sup> |
| **Caspase 3**    |                     |                     |
| CON              | 7373 ± 619<sup>a</sup> | 3037 ± 326<sup>a</sup> |
| LCS              | 4152 ± 409<sup>b</sup> | 2334 ± 202<sup>b</sup> |
| HCS              | 11,328 ± 1066<sup>c</sup> | 4845 ± 480<sup>c</sup> |

<sup>a</sup> Eight piglets per treatment. CON = pigs in the negative control group were fed a basal diet; LCS and HCS = pigs in coated cysteamine group were fed a basal diet supplemented with 35 and 280 mg/kg of cysteamine.
cysteamine has been used as a drug for the establishment of animal models of acute intestinal ulcers [17]. Plus, the characteristics such as deliquescence and pungent odors smell has to be modified by coating. However, differences in the control of the coating process and quality made the differences on the effects of supplemented coated cysteamines on the gastrointestinal mucosa.

The villi of intestine gradually became lower eventually forming a villous surface by subcutaneous or oral administration of cysteamine at 280 mg·kg\(^{-1}\) BW [18]. Cysteamine (100 mg·kg\(^{-1}\) bw) induced duodenal epithelial cell damage, marked exfoliation from the villous tip, was also observed at 1 h in rats after administration [19]. In this experiment, supplemented coated cysteamine at 35 mg·kg\(^{-1}\) improved the villus height and V:C, decreased crypt depth. It is consisted with the previous report, which showed cysteamine improved intestinal integrity [20]. Crypt lengthening is accompanied by intestinal damage when assessed histologically. HCS also improved intestinal morphology by decreasing the crypt depth, which could be attributed to the protection by coating technique in present study. However, coating technology is incapable to inhibit the damage of the intestinal mucosa by high levels CC. The ileal lesion was proportional to the level of dietary cysteamine, which may be due to the thorough release of cysteamine at the ileum.

After shorten the villi, defects in the epithelium, necrosis, inflammation of the lamina propria, and a

Table 3 Effects of coated cysteamine supplementation on jejunum mucosal protein, DNA and RNA contents of finishing pigs\(^a\)

| Index                | CON   | LCS   | HCS   | SEM   | P-value |
|----------------------|-------|-------|-------|-------|---------|
| Protein, mg/g tissue | 3.381 | 3.282 | 3.104 | 0.2300 | 0.8934  |
| RNA/DNA              | 1.978 | 1.904 | 0.7852| 0.3615| 0.03015 |
| Protein/DNA, mg/μg   | 0.0122| 0.0072| 0.0046| 0.0017| 0.1424  |

\(^a\)Eight piglets per treatment. CON = pigs in the negative control group were fed a basal diet; LCS and HCS = pigs in coated cysteamine group were fed a basal diet supplemented with 35 and 280 mg/kg of cysteamine.
localized ulcer developed in the gastric ulcer model administrated by cysteamine [18]. GI Lesions is the indicator to monitor the GI damage. The damage in intestine and stomach was attributed to the secretion of gastric acid promoted by cysteamine [7]. In present study, supplement coated cysteamine induced gastric damage even at 35 mg·kg−1 in diet. The reducing lesion score in LCS indicated the protection of cysteamine in intestine but not stomach. We found supplement cysteamine at 50 mg·kg−1 in diet damage the gastric mucosa with minor parakeratosis in the stomach in 2005 [21]. In many cases, cysteamine may have opposite effects on the same parameters, depend on the supplementation dose. Cysteamine acts as a gastric ulcerogenic at dose of 100 to 300 mg·kg−1, but also protects against ulcerogenic effects of other compound [16]. Although Intelligent Microcapsule Technology (IMT) was used to protect intestinal damage from cysteamine, the high level cysteamine in diet elevated the gastric lesion score, indicating the lower dose could be more suitable level of coated supplementation for pigs.

Activated caspases causes the changes in mitochondrial permeability and eventually led to apoptosis. Bcl-2 inhibited the activation of caspases in mitochondria and inhibited cell apoptosis. Bax is a cell apoptosis-promoting gene belonging to bcl-2 family. The overexpression of bax antagonizes the protection of bcl-2 and lead to apoptosis. Bcl-2 also has effects on antioxidation in animals. The apoptotic marker expression results indicated that as an endogenous compound, proper level of supplemented cysteamine may protect villus from apoptosis in the ileum, whereas dietary cysteamine may cause disturbance of physiological processes at abnormally high concentrations.

Coated cysteamine supplemented in pig diet could improve antioxidant status and delay meat discoloration by improving glutathione levels and antioxidase activity [22]. In mice, it showed protection against radioactivity in skin, vessels and the brain parenchyma (at around intraperitoneal doses of 250 mg·kg−1 bw) [23]. The mechanism for the protection was by the antioxidant synthesis such as glutathione [24]. In this study, T-SOD and DAO activity but not glutathione (data not showed), were elevated by supplement coated cysteamine at level of 35 mg·kg−1 diet, which is not in conformity with the previous reports. In rats, injected cysteamine inhibited DAO activity on two successive days at the dose of more than 400 mg·kg−1 bw, indicating that high cysteamine induced ulceration, which reduced the enzyme activity [25]. In vitro, cysteamine administration increased manganese superoxide dismutase (MnSOD) activity in cultured astroglia and protected these cells from subsequent H2O2 and mechanoenzymatic stress [26]. In addition, cysteamine was about 5 times as active (in terms of increased O2 consumption at pH 7.5) as the previously reported peroxidase-oxidase substrates NADPH, dihydroxymaric acid and indol-3-ylacetic acid in vitro [27]. The disparity in results may be explained by the differences in the animal organ, intake approach (including coated or not), dose and duration.

Conclusion
Taking together, supplemented coated cysteamine at 35 mg·kg−1 diet improved the ileum mucous healthy through regulating the oxidation status and expression of apoptosis-related proteins in pigs. Although IMT helped cysteamine to promote the intestine morphology such as reducing crypt depth, excess supplemented coated cysteamine in diet may cause damage on gastrointestinal mucous.

Methods
Animals, experimental design, and diets
The experimental protocol was approved by the Animal Welfare Committee of the Institute of Subtropical Agriculture, The Chinese Academy of Sciences. A total of 216 crossbred finishing pigs (Duroc × Landrace × Yorkshire) with an initial BW of 88.3 ± 0.3 kg provided by a commercial farm (Jiahe biotechnology co. LTD, Hunan, Changsha, China) was randomly assigned into 3 dietary groups, fed a corn-soybean powder diet containing 0 (control), 35 (LCS), and 280 (HCS) mg·kg−1 of cysteamine supplied as coated-cysteamine hydrochloride in diet for 29 days. The control diet met the nutrient requirements for finishing pigs recommended by the National Research Council (2012) and feed intakes were not affected by treatments [22]. In each group, pigs were housed in 8 pens (replicate) with 9 pigs/pen. The experiment was performed in a commercial farm (New Hope Liuhe Limited Liability Company, Yishui, China). All the animals had free access to feeds and drinking water. The basal diet met or exceeded nutrient requirements for pigs recommended by the NRC (2012) in the previous study [22]. Coated cysteamine hydrochloride, supplied by Hangzhou King Techina Technology Co., Ltd. (Hangzhou, China), contained 27% cysteamine hydrochloride. At the end of the experiment, one pig was randomly selected from each pen. The person who selected the pigs was blinded to all of the groups the pigs belonged in. Other animals were left to the farm. The selected pigs were killed by exsanguination after electrical stunning in the morning. After exsanguination, the stomach and small intestinal sample was collected. Approximately 20 cm of tissue was removed from the centre of the jejenum and ileum section [28]. Approximately 5 g intestinal tissue were flushed with ice-cold saline to recover mucosa. The mucosa samples were snap-frozen in liquid nitrogen and stored at −80 °C. Extra intestinal samples (2 cm) and stomach (2 g) samples were rinsed with precooling saline and fixed in formaldehyde solution for histological measurements [29].
**Analysis of intestinal mucosal protein, DNA and RNA contents**

Protein content of intestinal mucosal supernatant was analyzed by the method of Lowry et al. [30]. Mucosal DNA content was measured by a fluorometric assay [31]. RNA was determined by spectrophotometry by a modified Schmidt-Tannhauser method [32].

**Mucosal MDA, T-SOD, T-AOC and DAO activity**

Mucosal activities of Malondialdehyde (MDA), Superoxide Dismutase (SOD), and total antioxidative capacity (T-AOC) were measured using spectrophotometric kits in accordance with the manufacturer’s instructions (Nanjing Jiangcheng Biotechnology Institute, China). Diamine oxidase (DAO) was measured according to a previous report [33, 34].

**Evaluation of gastric and ileal mucosal lesions**

To estimate the severity of gastric and ileal erosions induced by CC, gastric, and intestinal damage was scored macroscopically on a scale of 0–3 based on the severity of hyperaemia and haemorrhagic erosions as previously described: 0, almost normal mucosa; 1, mild hyperaemia; 2, moderate hyperaemia and several erosions; and 3, severe hyperaemia and multiple erosions. Scoring was conducted by a person blind to treatment assignment [35].

**Determination of gastric and ileal morphology**

Haematoxylin and eosin (H & E) histological staining was performed on parallel sections of ileal tissue. Ileal tissue was immersed in 4% paraformaldehyde for 4 h and transferred to 70% ethanol. Individual lobes of ileal tissue biopsy material were placed in processing cassettes, dehydrated through a serial of alcohol gradient, and embedded in paraffin wax blocks. Ileal tissue was cut at 5 μm sections and dewaxed in xylene, rehydrated through decreasing concentrations of ethanol, washed in PBS, and then stained with haematoxylin and eosin. After staining, sections were dehydrated through increasing concentrations of ethanol and xylene. All specimens were examined under a light microscope (Nikon, Japan). Villus height and crypt depth were measured using an image-analysis system [36].

**Detection of cells positive for bcl-2, bax, and caspase-3 protein in gastrointestinal tract by immunohistochemistry**

The immunohistochemical staining was performed as described by Wu et al. [37]. Bcl-2, Bax, and Caspase-3 protein were localized in the gastrointestinal tract by immunohistochemistry as previously described [38]. The antibodies used were Anti-Bax (BA0315), Anti-Bcl-2 (BA0412), Anti-Caspase-3 (BA0588), and goat anti-mouse IgG (ZSGB-BIO SP Kit).

The bcl-2, bax, and Caspase-3 positive cells were counted using a computer-supported imaging system connected to a light microscope (OlympusAX70) with an objective magnification of ×400. Then, the Bcl-2, Bax, and Caspase-3 protein expression were quantified by Image-Pro Plus 5.1 (USA) image analysis software. Each group was measured in five sections and each section was measured in five fields and averaged.

**Statistical analysis**

All data were expressed as means and analyzed statistically by the one-way ANOVA using SPSS 20 (SPSS Inc., Chicago, IL, USA). Each pig was considered an experimental unit. Duncan’s multiple-range test was performed to identify differences between significant mean values. The differences were declared significant at $P < 0.05$ and a trend at $0.05 < P < 0.10$ in all analyses, unless otherwise stated.

**Abbreviations**

bam: Bcl-2-associated X protein; bcl-2: B-cell lymphoma-2; caspase: cysteine-aspartic proteases; CC: Coat cysteamine; DAO: Diamine oxidase; GI: Gastrointestinal; IMT: Intelligent Microcapsule Technology; MDA: Malondialdehyde; MnSOD: Manganese superoxide dismutase; SOD: Superoxide Dismutase; T-AOC: Total antioxidative capacity

**Acknowledgements**

We thank Hangzhou King Technia Technology Company Academician Expert workstation for providing technical assistance.

**Ethical approval ethics approval and consent to participate**

The experimental protocol was approved by the Animal Welfare Committee of the Institute of Subtropical Agriculture, The Chinese Academy of Sciences. Explicit owner informed consent for inclusion of animals in this study was signed.

**Authors’ contributions**

HL designed the study, and analyzed data, drafted the manuscript with MB. MB conducted the research. XX and BT participated in experimental design and statistical analysis. RY provided the methods to coat the cysteamine. RH and YY participated in experimental design and helped draft the manuscript. Additionally, HL had final responsibility for content while all authors read and approved the final manuscript.

**Funding**

We would like to express sincere gratitude to the National Key Research and Development Program of China (2018YFD0501210) and Natural Science Foundation of Hunan Province of China (2018JJ3579). The research was also funded by the research program of Youth Talent Program of Hunan Province (2018BS3110), Youth Innovation Team Project of IFA, CAS (2017QNCXTD_TBE) and the China Agriculture Research System (CARS-35).

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available to preserve the individual pigs’ and their owners’ privacy, but are available from the corresponding author on reasonable request.

**Consent for publication**

Prior to study enrolment, written owner consent was obtained for each pig.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Scientific Observing and Experimental Station of Animal Nutrition and Feed Science in South-Central, Ministry of Agriculture, Hunan Provincial Engineering Research Center for Healthy Breeding of Livestock and Poultry, Key Laboratory of Agro-ecological Processes in Subtropical Region, Institute
References

1. Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother. 2004;5(11):2255–62.

2. Wühl E, Haffner D, Offner G, Broyer M, van Hoff W, Melci O. Cystinosis ESGGHTICwN Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr. 2001;138(6):880–7.

3. Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab. 1995;80(1):3257–61.

4. Yang CB, Li AK, Yin YL, Huang RL, Li TJ, Li LL, Liao YP, Deng ZY, Zhang J, Wang B. Effects of dietary supplementation of cysteamine on growth performance, carcass quality, serum hormones and gastric ulcer in finishing pigs. J Sci Food Agric. 2005;85(11):1947–52.

5. Liu G, Wei Y, Wang Z, Wu D, Zhou A. Effects of dietary supplementation with cysteamine on growth hormone receptor and insulin-like growth factor system in finishing pigs. J Agric Food Chem. 2008;56(13):5422–7.

6. Dunshea F. Porcine somatotropin and cysteamine hydrochloride improve growth performance and reduce back fat in finisher gilts. Aust J Exp Agric. 2007;47(7):796–800.

7. Kirkgard P, Poulsen SS, Lound F, Halse C, Christiansen J. Cysteamine-induced duodenal ulcer and acid secretion in the rat. Scand J Gastroenterol. 1980;15(5):621–4.

8. Pfeiffer D, Pfeiffer C, Szabo S. Development of cysteamine-induced ulcerator model for the study of gastric ulceration in rats. J Exp Pathol. 1997;81(1):295–302.

9. Selvy H, Szabo S. Experimental model for production of perforating duodenal ulcers by cysteamine in the rat. Nature. 1973;244:458–9.

10. Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA. The evaluation of cysteamine associated with different energy constituents. Mamm Protein Metab. 1969:3:423–525.

11. Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA. The effects of cysteamine on the upper gastrointestinal tract in pigs. Exp Pathol. 1977;58(1):1–5.

12. Wenner WJ, Murphy JL. The effects of cysteamine on the upper gastrointestinal tract of children with cystinosis. Pediatr Nephrol. 1997;11(5):600–3.

13. Brenner E, Fleschko G, Kivlaakso E. Cysteamine and propionitrile inhibit the rise of duodenal mucosal alkaline secretion in response to luminal acid in rats. Gastroenterology. 1985;88(2):295–302.

14. Tatch P.J. Polymers for controlled drug delivery: CRC press; 1990.

15. Dohil R, Fidler M, Barshop BA, Gangoti J, Deutsch R, Martin M, Schneider JA. Understanding intestinal cysteamine absorption. J Pediatr. 2006;148(6):764–9.

16. Young D, Jun Z, Bin W, et al. Effects of dietary supplementation of cysteamine on growth performance, carcass quality, serum hormones and gastric ulcer in finishing pigs. J Sci Food Agric. 2005;85(11):1947–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions